Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

259
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
259
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

6.2K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
6.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

11.6K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
11.6K
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

369
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
369
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence01:19

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

241
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
241

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sabbatical.

Academic medicine : journal of the Association of American Medical Colleges·2026
Same author

Complement biomarkers during iptacopan treatment.

Lancet (London, England)·2026
Same author

C4b-binding protein as an antigenic target in the pathogenesis of antiphosphatidylethanolamine autoantibodies.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Association of Carboxypeptidase B2 Gene Polymorphisms With Graft Loss in Kidney Transplantation.

Transplantation direct·2026
Same author

Endothelial cell-released CD93 contributes to podocyte injury in idiopathic nephrotic syndrome.

Science translational medicine·2026
Same author

Autoantibodies reactive with glomerular endothelial cells and podocytes in patients with membranous nephropathy.

Journal of translational autoimmunity·2026

Related Experiment Video

Updated: May 1, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.0K

New anti-complement drugs: not so far away.

Joshua M Thurman1

  • 1UNIVERSITY OF COLORADO DENVER.

Blood
|March 29, 2014
PubMed
Summary

Small-molecule inhibitors targeting C3 cleavage effectively block complement activation in paroxysmal nocturnal hemoglobinuria (PNH) erythrocytes. These compounds achieve therapeutic levels following subcutaneous delivery in nonhuman primates, suggesting potential PNH treatment efficacy.

Area of Science:

  • Hematology
  • Immunology
  • Drug Discovery

Background:

  • Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder characterized by complement-mediated destruction of erythrocytes.
  • Complement system activation on PNH cells leads to chronic hemolysis and thrombotic complications.

Purpose of the Study:

  • To evaluate the efficacy of small-molecule inhibitors of C3 cleavage in preventing complement activation on PNH erythrocytes.
  • To assess the pharmacokinetic profile of these inhibitors after subcutaneous administration in nonhuman primates.

Main Methods:

  • In vitro assessment of complement activation on patient-derived PNH erythrocytes.
  • Pharmacokinetic studies in nonhuman primates following subcutaneous injection of C3 cleavage inhibitors.

More Related Videos

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

11.5K
Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

21.0K

Related Experiment Videos

Last Updated: May 1, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.0K
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

11.5K
Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

21.0K

Main Results:

  • Small-molecule inhibitors of C3 cleavage demonstrated a significant reduction in complement activation on PNH erythrocytes.
  • These inhibitors reached therapeutically relevant concentrations in nonhuman primates after subcutaneous injection.

Conclusions:

  • Targeting C3 cleavage represents a promising therapeutic strategy for paroxysmal nocturnal hemoglobinuria.
  • Subcutaneous administration of these inhibitors is feasible and achieves effective drug concentrations for potential clinical application.